This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LifeAgain Announces Recognition Of National Prostate Cancer Awareness Month

SAN DIEGO, Sept. 20, 2013 /PRNewswire/ -- LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced its recognition of National Prostate Cancer Awareness Month.  September 2013 has been declared National Prostate Awareness Month by Presidential Proclamation to "raise awareness, support research, improve care, and reduce the impact of this disease on our citizens and our Nation." 

(Logo: http://photos.prnewswire.com/prnh/20130919/LA82808LOGO)  

Prostate cancer is the most common non-skin cancer in America, affecting 1 in 6 men. In 2013, more than 238,000 men will be diagnosed with prostate cancer, and more than 30,000 men will die from the disease.  It is estimated that over the next 10 years in the United States, approximately 8 million men under age 64 will be determined to have elevated PSA scores (prostate-specific antigen) without formal determination of prostate cancer, and 1 million men under age 64 will be diagnosed with prostate cancer.  Overall, 1.6 million men have elevated PSA, and about 30 percent of them will be diagnosed with prostate cancer.

Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional life insurance underwriting standards.  Pioneering this field, LifeAgain recently introduced the first term life insurance for men with active localized prostate cancer. LifeAgain's BlueMetric Selectâ„¢ program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Importantly, it is available to prostate cancer patients who are in a "watchful waiting" treatment plan, including younger men who traditionally have been denied life insurance with few exceptions.  The BlueMetric Select program was developed based on LifeAgain's Advanced Medical Data Analytics Platform Technology (ADAPTâ„¢).  Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About LifeAgain

LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of "survivable risk" term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain's initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com.

Forward-Looking Statements

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and subject to change. Moreover, we operate in a rapidly changing and competitive environment. These uncertainties and contingencies could cause actual results to differ materially from those expressed, and therefore undue reliance should not be placed upon such statements.  The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.     

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs